MannKind | MNKD - Pre Tax Profit


MannKind reported $-16.37M in Pre-Tax Profit for its fiscal quarter ending in March of 2026.





Pre Tax Profit Change Date
Adma Biologics USD 57.13M 4.47M Mar/2026
BioCryst Pharmaceuticals USD 248.02M 235.89M Dec/2025
Eli Lilly USD 8.85B 583.8M Mar/2026
Halozyme Therapeutics USD 180.33M 281.18M Mar/2026
Insmed USD -11.37M 150.72M Jun/2026
Karyopharm Therapeutics USD -22.39M 17.51M Mar/2026
MacroGenics USD -36.77M 21.84M Mar/2026
MannKind USD -16.37M 4.56M Mar/2026
Merck USD -3.53B 6.95B Mar/2026
Minerva Neurosciences USD 22.51M 30.74M Sep/2024
Novavax USD 17.9M 220.94M Dec/2025
Novo Nordisk DKK 62.17B 36.66B Mar/2026
Pfizer USD -653M 5.84B Jun/2026
Sanofi EUR 837M 1.17B Jun/2026
Xencor USD -21.92M 106.72M Jun/2026